• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

    7/15/25 8:45:00 AM ET
    $ABT
    $DXCM
    $IRTC
    $TNDM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABT alert in real time by email

    MarketNewsUpdates News Commentary

    NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies.  AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often develop unnoticed by patients and might not be detected during routine exams. By identifying these signs early, AI enhances the ability to initiate treatments promptly, significantly improving health outcomes. This proactive approach allows for timely intervention, which is crucial in preventing the progression of these eye diseases.  AI enhances patient care by analyzing the risk of disease progression and the specifics of each patient's retinal condition. This analysis helps healthcare providers develop customized treatment plans, tailored to individual needs. AI can predict how diseases like AMD will progress and helps in optimizing treatment schedules. This personalized approach ensures that each patient receives the most effective care specific to their condition, potentially improving their quality of life.  A report from Media.Market.us said that the Global AI-Powered Retina Image Analysis Market Size is projected to expand significantly, reaching approximately US$ 9.4 billion by 2033, up from US$ 2.65 billion in 2023. This growth, at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2033, is fueled by several pivotal developments in the field of ophthalmology, driven by advances in artificial intelligence (AI).  Active healthcare/tech companies active in the diabetes treatment industry include: Avant Technologies Inc. (OTCQB:AVAI), Abbott (NYSE:ABT), DexCom, Inc. (NASDAQ:DXCM), iRhythm Technologies, Inc. (NASDAQ:IRTC), Tandem Diabetes Care, Inc. (NASDAQ:TNDM).

    Media.Market.us continued: "Enhanced Patient Monitoring through AI: AI-powered tools are revolutionizing the monitoring of retinal diseases. These tools enable continuous observation, allowing doctors to track disease progression over time. This ongoing monitoring is crucial for chronic conditions, where timely adjustments to treatment can lead to better management of the disease. Continuous data collection provided by AI tools offers a dynamic view of the patient's condition, facilitating more informed decision-making in clinical practice.  Expanding Access to Care with AI in Ophthalmology: AI technology can significantly extend the reach of specialized eye care, especially to remote or underserved communities. Through AI, high-quality diagnostic and monitoring services can be delivered remotely, eliminating the need for patients to travel to specialist centers. This capability not only saves time and resources but also ensures that more patients have access to necessary care, improving eye health outcomes across diverse populations.  Supporting Research and Development in Ophthalmology: AI applications in retina image analysis contribute valuable data to the field of ophthalmology. This data aids in ongoing research, offering new insights into how retinal diseases develop and progress. Researchers can use this information to explore potential new treatments and understand disease mechanisms more deeply. AI's role in R&D not only accelerates scientific discovery but also opens up possibilities for innovative therapeutic approaches, enhancing patient care."

    Avant Technologies, Inc. (OTCQB:AVAI) and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA - Avant Technologies, Inc. ("Avant" or the "Company") and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the completion of its milestone meeting with the U.S. Food and Drug Administration (FDA). The pre-submission meeting allowed Ainnova and its Contract Research Organization (CRO), Fortrea, to present and discuss Ainnova's planned clinical trial for its Vision AI platform in the early detection of diabetic retinopathy and receive critical feedback from the FDA.

    Ainnova's clinical trial will be conducted exclusively in the United States and focus solely on diabetic retinopathy. The FDA has now provided the Company with valuable guidance on its clinical protocol, the number and type of clinics Ainnova will need to conduct a successful clinical trial, the number of retinologists required to examine the images generated by Ainnova's Vision AI, etc.

    With the FDA's recommendations, the Company can now actively plan for the total cost of conducting this planned clinical trial through to completion. Data from Ainnova's trial will support the Company's FDA 510(k) submission to obtain clearance from the FDA to market the Vision AI technology in the United States.

    Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We're truly excited about this next phase. We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists.

    "This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera, which we believe will be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care."

    AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's clinical trial is paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.  CONTINUED… Read this and more news for Avant Technologies at:  https://finance.yahoo.com/quote/AVAI/news/

    In other diabetes developments and happenings in the biotech market include:

    Abbott (NYSE:ABT) recently announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus* sensor, is now available to Canadians living with diabetes. This innovative product features the world's smallest1,2 glucose sensor.

    Glucose monitoring is key to effective diabetes management as it helps people living with diabetes understand how their body responds to food, exercise, and medications3. It empowers them to take an active role in managing their condition, which can ultimately increase confidence4 and improve health outcomes.

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, recently released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States.

    During the conference, Dexcom will present extensive clinical data that shows the benefits of CGM for those living with Type 2 diabetes as well as new outcomes from early Stelo users. Dexcom releases new State of Type 2 Report: Access and Attitudes Across the United States  -  Earlier this year, Dexcom announced the release of its first multi-region report, detailing access and attitudes of individuals diagnosed with Type 2 diabetes and healthcare professionals across Europe and the Middle East (EMEA).

    iRhythm Technologies, Inc. (NASDAQ:IRTC) recently announced the results from two large-scale real-world studies presented at the American Diabetes Association's 85th Scientific Sessions (ADA 2025). The analyses reveal that cardiac arrhythmias are common and often occur early in people with type 2 diabetes (T2D)—especially those who also have chronic kidney disease (CKD). These findings suggest a critical opportunity to enhance early detection strategies in at-risk cardiometabolic populations.

    The studies examined longitudinal claims data from over 30 million U.S. adults, providing new insights into how arrhythmias—often asymptomatic—cluster around major disease inflection points. In T2D patients, arrhythmias were frequently identified prior to or shortly after diagnoses of CKD or major adverse cardiovascular events such as stroke or heart failure.

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, recently announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025.

    "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs," said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. "The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology."

    DISCLAIMER:  MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  MNU is NOT affiliated in any manner with any company mentioned herein.  MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  MNU is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed MNU was compensated twenty two hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party.  MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

    Contact Information:

    Media Contact email: [email protected] - +1(561)325-8757

    Cision View original content:https://www.prnewswire.com/news-releases/artificial-intelligence-revolutionizing-early-detection-of-diabetic-retinopathy-creating-a-multi-billion-dollar-revenue-opportunity-302505344.html

    SOURCE MarketNewsUpdates

    Get the next $ABT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $DXCM
    $IRTC
    $TNDM

    CompanyDatePrice TargetRatingAnalyst
    iRhythm Technologies Inc.
    $IRTC
    9/23/2025$185.00In-line
    Evercore ISI
    Tandem Diabetes Care Inc.
    $TNDM
    9/8/2025$22.00Outperform
    Oppenheimer
    DexCom Inc.
    $DXCM
    9/8/2025Outperform → Perform
    Oppenheimer
    DexCom Inc.
    $DXCM
    8/21/2025$100.00Buy
    Argus
    iRhythm Technologies Inc.
    $IRTC
    8/20/2025$200.00Buy
    BofA Securities
    Tandem Diabetes Care Inc.
    $TNDM
    8/12/2025$10.35Sell → Neutral
    Citigroup
    Tandem Diabetes Care Inc.
    $TNDM
    8/7/2025$14.00Overweight → Neutral
    Piper Sandler
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    More analyst ratings

    $ABT
    $DXCM
    $IRTC
    $TNDM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States

    Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.). "This latest milestone reinforces our commitment to facilitating choice and access for people who rely on insulin therapy," said Jordan Pinsker, MD, Chief Medical Officer at Tandem Diabetes Care. "This clearance allows people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes to use Lyumjev with the t:slim X2 i

    9/29/25 8:30:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Abbott's Dissolving Stent Receives Health Canada Approval for Treating Blocked Arteries Below-the-Knee

    More than 800,000 Canadians1 live with peripheral artery disease (PAD) with limited treatment options to date1The first-of-its-kind dissolvable stent, the Esprit™ BTK Everolimus Eluting Resorbable Scaffold, dissolves over time after it has opened blocked arteries below-the-knee (BTK)The dissolving stent offers the possibility of better outcomes for people with the most severe form of PADTORONTO, Sept. 29, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that Health Canada has authorized the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a first-of-its kind treatment innovation for people with chronic limb threatening ischemia (CLTI) below-the-knee (BTK). The E

    9/29/25 8:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Hosts Conference Call for Third-Quarter Earnings

    ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at https://www.abbott.com/investors.html. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in dia

    9/24/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $DXCM
    $IRTC
    $TNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Carpenter Rick converted options into 406 shares and covered exercise/tax liability with 207 shares, increasing direct ownership by 0.89% to 22,566 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    9/16/25 4:47:14 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF COMMERCIAL OFFICER Novara Mark David converted options into 7,415 shares and covered exercise/tax liability with 3,866 shares, increasing direct ownership by 12% to 32,348 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    9/16/25 4:47:08 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Director Malady Kyle sold $53,934 worth of shares (667 units at $80.86), decreasing direct ownership by 3% to 22,667 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    9/9/25 4:18:20 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $ABT
    $DXCM
    $IRTC
    $TNDM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Sheridan John F bought $102,318 worth of shares (10,000 units at $10.23), increasing direct ownership by 10% to 106,327 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 6:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh bought $149,404 worth of shares (13,720 units at $10.89) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 5:18:51 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    3/11/25 6:06:01 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $ABT
    $DXCM
    $IRTC
    $TNDM
    SEC Filings

    View All

    DexCom Inc. filed SEC Form 8-K: Leadership Update

    8-K - DEXCOM INC (0001093557) (Filer)

    9/15/25 7:30:47 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by iRhythm Technologies Inc.

    144 - iRhythm Technologies, Inc. (0001388658) (Subject)

    8/11/25 4:18:39 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Inc. filed SEC Form 8-K: Other Events

    8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

    8/7/25 4:09:32 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $ABT
    $DXCM
    $IRTC
    $TNDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on iRhythm with a new price target

    Evercore ISI initiated coverage of iRhythm with a rating of In-line and set a new price target of $185.00

    9/23/25 8:17:27 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Tandem Diabetes Care with a new price target

    Oppenheimer initiated coverage of Tandem Diabetes Care with a rating of Outperform and set a new price target of $22.00

    9/8/25 8:59:21 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Dexcom downgraded by Oppenheimer

    Oppenheimer downgraded Dexcom from Outperform to Perform

    9/8/25 8:40:02 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $ABT
    $DXCM
    $IRTC
    $TNDM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $DXCM
    $IRTC
    $TNDM
    Leadership Updates

    Live Leadership Updates

    View All

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $DXCM
    $IRTC
    $TNDM
    Financials

    Live finance-specific insights

    View All

    Abbott Hosts Conference Call for Third-Quarter Earnings

    ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at https://www.abbott.com/investors.html. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in dia

    9/24/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Declares 407th Consecutive Quarterly Dividend

    ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 407th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 17, 2025, to shareholders of record at the close of business on Oct. 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfol

    9/19/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NYSE Content Advisory: Pre-Market update + Wall Street braces for Nvidia's earnings

    NEW YORK, Aug. 27, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on August 27th Equities are up this morning as investors wait for chip giant Nvidia's Q2 earnings report. The company is set to release the earnings after market close this afternoon.As the most heavily weighted company in the S&P 500 at more than 8%, Nvidia's results will likely be felt by investors throughout the rest of the week and provide insight into the level of demand for AI.The

    8/27/25 8:55:00 AM ET
    $ABT
    $ICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    $ABT
    $DXCM
    $IRTC
    $TNDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 9:52:49 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care